- Home
- CRIS vs DARE Comparison
CRIS vs DARE Comparison
Compare CRIS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- DARE
- Stock Information
- Founded
- CRIS 2000
- DARE 2015
- Country
- CRIS United States
- DARE United States
- Employees
- CRIS N/A
- DARE N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- DARE Health Care
- Exchange
- CRIS Nasdaq
- DARE Nasdaq
- Market Cap
- CRIS 22.9M
- DARE 26.3M
- IPO Year
- CRIS 2000
- DARE N/A
- Fundamental
- Price
- CRIS $1.71
- DARE $2.12
- Analyst Decision
- CRIS Strong Buy
- DARE Strong Buy
- Analyst Count
- CRIS 2
- DARE 1
- Target Price
- CRIS $16.50
- DARE $12.00
- AVG Volume (30 Days)
- CRIS 70.9K
- DARE 253.9K
- Earning Date
- CRIS 08-05-2025
- DARE 08-14-2025
- Dividend Yield
- CRIS N/A
- DARE N/A
- EPS Growth
- CRIS N/A
- DARE N/A
- EPS
- CRIS N/A
- DARE N/A
- Revenue
- CRIS $11,405,000.00
- DARE N/A
- Revenue This Year
- CRIS N/A
- DARE $74,787.57
- Revenue Next Year
- CRIS $9.52
- DARE $141.76
- P/E Ratio
- CRIS N/A
- DARE N/A
- Revenue Growth
- CRIS 12.24
- DARE N/A
- 52 Week Low
- CRIS $1.02
- DARE $1.83
- 52 Week High
- CRIS $8.29
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- CRIS 48.40
- DARE 42.66
- Support Level
- CRIS $1.47
- DARE $2.00
- Resistance Level
- CRIS $1.79
- DARE $2.35
- Average True Range (ATR)
- CRIS 0.14
- DARE 0.15
- MACD
- CRIS 0.01
- DARE 0.01
- Stochastic Oscillator
- CRIS 57.32
- DARE 47.70
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.